You're signed outSign in or to get full access.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a leading American biotechnology company headquartered in Tarrytown, New York, with over 15,100 employees across 12 countries. Founded in 1988, it invents, develops, manufactures, and commercializes life-transforming medicines for people with serious diseases, addressing conditions such as eye diseases, cancer, allergic and inflammatory diseases, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. The company is publicly traded on the NASDAQ and is known for its robust internal research culture and extensive global clinical development.
Investment Strategy
Regeneron Pharmaceuticals operates as a fully integrated biotechnology firm, focusing on scientific innovation to create therapies for unmet medical needs. The company's investment and research strategy centers around the invention, development, and commercialization of biologic medicines through its own laboratories. Regeneron advances candidates across multiple therapeutic areas, including ophthalmology, immunology, oncology, cardiology, hematology, neurology, infectious disease, and rare diseases. Its approach emphasizes internally discovered, homegrown assets, complemented by collaborations and strategic acquisitions that expand its pipeline and global impact.
Latest 13F Filing Activity
Regeneron Pharmaceuticals, Inc. filed their most recent 13F report on Jun 30, 2025 disclosing 4 equity positions with a total 13F market value of $1B. The fund increased holdings in Alnylam Pharmaceuticals, Inc., Intellia Therapeutics, Inc., Adicet Bio, Inc. among other positions. Regeneron Pharmaceuticals, Inc. reduced exposure to 2seventy Bio, Inc., Adverum Biotechnologies, Inc., Adicet Bio, Inc. among others.
Top Holdings
Equity Positions (4)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
A ALNY | Alnylam Pharmaceuticals, Inc. | 97.59% | $1.45B | 4,444,445 | $235.31 | $326.09 | +$249.2M |
N NTLA | Intellia Therapeutics, Inc. | 2.34% | $34.7M | 3,702,995 | $11.66 | $9.38 | +$8.4M |
A ACET | Adicet Bio, Inc. | 0.04% | $590.6K | 968,183 | $0.96 | $0.61 | -$140.4K |
A ADVM | Adverum Biotechnologies, Inc. | 0.03% | $389.0K | 180,909 | $4.67 | $2.15 | -$401.6K |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more